Learn more about Myllia and our powerful CROP-Seq technology for target discovery

We utilise the CROP-Seq (for “CRISPR Droplet Sequencing”) workflow, developed by Myllia´s co-founder Christoph Bock, to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next generation CRISPR screens. Our powerful approach has broad applications in identifying novel drug targets, elucidating unknown mechanisms of actions of drugs and understanding genetic variants linked to disease risk

The CRISPR screening team at Myllia Biotechnology GmbH in front of a brick wall in Vienna, Austria

Our end-to-end platform for tailor-made CRISPR screens

Myllia has built an end-to-end genetic screening platform. We routinely conduct screens using hundreds of thousands of single cells in one experiment and intend to scale the technology even further.

  • Customized assay development for cellular models, incl. primary cells
  • Proprietary guide RNA design algorithms for CRISPRn/i/a
  • Proprietary primer panel designs for targeted sequencing (TA-seq)
  • Cloning and manufacturing of lentiviral guide RNA libraries
  • Performance of the actual CRISPR screens
  • Single-cell library prep and NGS (WTA and TA-seq)
  • Bioinformatic analysis and target deconvolution

Get in touch with Myllia's leadership and CROP-Seq experts

Picture of Vienna by Night.